Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Mol Cell Biochem ; 434(1-2): 7-15, 2017 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-28397014

RESUMEN

Geraniol, an acyclic monoterpene found in lemon grass and aromatic herb oil, has been shown to exert antitumor and antioxidant activities against various cancer types. The objective of this study was to investigate the potential chemoprotective role of geraniol against 4-nitroquinoline-1-oxide (4NQO)-induced oral carcinogenesis in male Wistar rats and furthermore to study anti-inflammatory mechanisms of action through possible NF-κB signaling. 4NQO was administered to rats at the dose of 50 ppm through drinking water to induce tongue cancer in 20 weeks. 4NQO provoked inflammation by upregulating the expressions of the p65 subunit nuclear factor kappa-ß (NF-κB) in the nucleus, tumor necrosis factor-α (TNF-α), interleukin-1ß (IL-1ß), cyclooxygenase-2 (COX-2), and inducible nitric oxide synthase (iNOS). Additionally, staining for immature and mature mast cells in cancer niche by toluidine blue staining and alcian blue-safranin staining showed more accumulation. Co-treatment of geraniol 200 mg/kg b.w. showed a significant decrease in the level of p65 NF-κB in the nucleus, and this might be due to the inhibition of NF-κB activation/translocation into nucleus, which was further confirmed by decreased immature and mature mast cell density and the expression of inflammatory downstream mediators such as TNF-α, IL-1ß, COX-2, and iNOS. Collectively, our results suggested that geraniol as a potential anti-inflammatory agent having the capability to obstruct 4NQO initiated NF-κB activation and modulated the expression of inflammatory mediators.


Asunto(s)
Anticarcinógenos/uso terapéutico , Carcinógenos/toxicidad , Regulación hacia Abajo/efectos de los fármacos , FN-kappa B/metabolismo , Quinolonas/toxicidad , Terpenos/farmacología , Neoplasias de la Lengua/prevención & control , 4-Nitroquinolina-1-Óxido/toxicidad , Monoterpenos Acíclicos , Animales , Recuento de Células Sanguíneas , Western Blotting , Inflamación/complicaciones , Inflamación/metabolismo , Mediadores de Inflamación/metabolismo , Masculino , Ratas , Ratas Wistar , Neoplasias de la Lengua/inducido químicamente , Neoplasias de la Lengua/complicaciones , Neoplasias de la Lengua/metabolismo
2.
Fundam Clin Pharmacol ; 28(3): 310-22, 2014 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-23834621

RESUMEN

The lungs mainly serve as a primary site for xenobiotic metabolism and constitute an important defense mechanism against inhalation of carcinogens. Our current study aimed to evaluate the chemotherapeutic efficacy of baicalein (BE) in Swiss albino mice exposed to tobacco-specific carcinogen benzo(a)pyrene [B(a)P] for its ability to mitigate pulmonary carcinogenesis. Here, we report that altered activities/levels of lysosomal enzymes (cathepsin-D, cathepsin-B, acid phosphatase, ß-D-galactosidase, ß-D-glucuronidase, and ß-D-N-acetyl glucosaminidase), phase I biotransformation enzymes (cytochrome P450, cytochrome b5, NADPH-cytochrome P450 reductase, and NADH-cytochrome b5 reductase), and phase II enzymes (glutathione S-transferase, UDP-glucuronyl transferase, and DT-diaphorase) were observed in the B(a)P-induced mice. Treatment with BE significantly restored back the activities/levels of lysosomal enzymes, phase I and phase II biotransformation enzymes. Moreover, assessment of lysosomal abnormalities by transmission electron microscopic examination revealed that BE treatment effectively counteract B(a)P-induced oxidative damages. Protein expression levels studied by immunohistochemistry, immunofluorescence, and immunoblot analysis of CYP1A1 revealed that BE treatment effectively negate B(a)P-induced upregulated expression of CYP1A1. Further analysis of scanning electron microscopic studies in lung was carried out to substantiate the anticarcinogenic effect of BE. The overall data suggest that BE treatment significantly inhibits lysosomal and microsomal dysfunction, thus revealing its potent anticarcinogenic effect.


Asunto(s)
Anticarcinógenos/uso terapéutico , Benzo(a)pireno/toxicidad , Flavanonas/uso terapéutico , Neoplasias Pulmonares/enzimología , Pulmón/efectos de los fármacos , Lisosomas/enzimología , Xenobióticos/farmacocinética , Animales , Anticarcinógenos/administración & dosificación , Benzo(a)pireno/farmacocinética , Western Blotting , Citocromo P-450 CYP1A1/biosíntesis , Flavanonas/administración & dosificación , Inmunohistoquímica , Pulmón/enzimología , Pulmón/ultraestructura , Neoplasias Pulmonares/inducido químicamente , Neoplasias Pulmonares/patología , Neoplasias Pulmonares/prevención & control , Lisosomas/efectos de los fármacos , Lisosomas/ultraestructura , Masculino , Fase I de la Desintoxicación Metabólica , Fase II de la Desintoxicación Metabólica , Ratones , Microscopía Electrónica de Rastreo , Microscopía Electrónica de Transmisión
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...